Lixte Biotechnology Holdings Stock Price on May 10, 2024
| LIXT Stock | USD 2.61 0.11 4.40% |
Below is the normalized historical share price chart for Lixte Biotechnology Holdings extending back to September 21, 2007. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Lixte Biotechnology stands at 2.61, as last reported on the 27th of June, with the highest price reaching 2.69 and the lowest price hitting 2.59 during the day.
If you're considering investing in Lixte Stock, it is important to understand the factors that can impact its price. Lixte Biotechnology has Sharpe Ratio of -0.0658, which conveys that the firm had a -0.0658% return per unit of risk over the last 3 months. Lixte Biotechnology exposes thirty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Lixte Biotechnology's Risk Adjusted Performance of 0.047, mean deviation of 4.55, and Downside Deviation of 6.82 to check out the risk estimate we provide.
At this time, Lixte Biotechnology's Total Stockholder Equity is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 51.4 M in 2024, whereas Common Stock is likely to drop 213.75 in 2024. . At this time, Lixte Biotechnology's Price Book Value Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 0.01 in 2024, whereas Price To Operating Cash Flows Ratio is likely to drop (1.10) in 2024. Lixte Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 21st of September 2007 | 200 Day MA 2.5128 | 50 Day MA 2.7018 | Beta (0.21) |
Lixte |
Sharpe Ratio = -0.0658
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LIXT |
Estimated Market Risk
| 5.47 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.36 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lixte Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lixte Biotechnology by adding Lixte Biotechnology to a well-diversified portfolio.
Price Book 15.548 | Book Value (0.17) | Enterprise Value 6 M | Enterprise Value Ebitda (1.38) | Shares Float 2 M |
Lixte Biotechnology Main Headline on 10th of May 2024
Acquisition by Kovach John S of 21100 shares of Lixte Biotec... by Kovach John S
Filed transaction by Lixte Biotechnology Holdings Director, 10 Percent Owner, Officer President And Ceo. Grant, award or other acquisition pursuant to Rule 16b-3
Lixte Biotechnology Valuation on May 10, 2024
It is possible to determine the worth of Lixte Biotechnology on a given historical date. On May 10, 2024 Lixte was worth 2.75 at the beginning of the trading date compared to the closed value of 2.56. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Lixte Biotechnology stock. Still, in general, we apply an absolute valuation method to find Lixte Biotechnology's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lixte Biotechnology where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Lixte Biotechnology's related companies.
| Open | High | Low | Close | Volume | |
| 2.74 | 2.75 | 2.63 | 2.72 | 18,694 | |
05/10/2024 | 2.75 | 2.82 | 2.48 | 2.56 | 13,533 |
| 2.75 | 2.78 | 2.67 | 2.67 | 3,804 |
| Backtest Lixte Biotechnology | | | Lixte Biotechnology History | | | Lixte Biotechnology Valuation | Previous | Next |
Lixte Biotechnology Trading Date Momentum on May 10, 2024
| On May 13 2024 Lixte Biotechnology Holdings was traded for 2.67 at the closing time. The top price for the day was 2.78 and the lowest listed price was 2.67 . The trading volume for the day was 3.8 K. The trading history from May 13, 2024 was a factor to the next trading day price appreciation. The trading delta at closing time against the next closing price was 4.30% . The trading delta at closing time against the current closing price is 4.30% . |
Lixte Biotechnology Fundamentals Correlations and Trends
By evaluating Lixte Biotechnology's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Lixte financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Lixte Biotechnology Stock history
Lixte Biotechnology investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Lixte is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Lixte Biotechnology will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Lixte Biotechnology stock prices may prove useful in developing a viable investing in Lixte Biotechnology
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 1.9 M | 1.8 M | |
| Net Loss | -6.1 M | -5.8 M |
Lixte Biotechnology Quarterly Net Working Capital |
|